330 related articles for article (PubMed ID: 37417358)
21. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for nasopharyngeal cancer-a review.
Jain A; Chia WK; Toh HC
Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Yeo ELL; Li YQ; Soo KC; Wee JTS; Chua MLK
Chin Clin Oncol; 2018 Apr; 7(2):15. PubMed ID: 29764160
[TBL] [Abstract][Full Text] [Related]
24. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
25. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
[TBL] [Abstract][Full Text] [Related]
26. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Tsang CM; Tsao SW
Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
[TBL] [Abstract][Full Text] [Related]
27. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.
Chen H; Duan X; Deng X; Huang Y; Zhou X; Zhang S; Zhang X; Liu P; Yang C; Liu G; Ren Q; Xiong Y; Zhu B; Zhang J; Xiang T
Cancer Immunol Res; 2023 Jun; 11(6):830-846. PubMed ID: 36996321
[TBL] [Abstract][Full Text] [Related]
28. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
Lee AZE; Tan LSY; Lim CM
Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
[TBL] [Abstract][Full Text] [Related]
29. Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.
Ahmed N; Abusalah MAHA; Farzand A; Absar M; Yusof NY; Rabaan AA; AlSaihati H; Alshengeti A; Alwarthan S; Alsuwailem HS; Alrumaih ZA; Alsayyah A; Yean CY
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676626
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
31. Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma.
Renaud S; Lefebvre A; Mordon S; Moralès O; Delhem N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560253
[TBL] [Abstract][Full Text] [Related]
32. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
33. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
[TBL] [Abstract][Full Text] [Related]
35. The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Png YT; Yang AZY; Lee MY; Chua MJM; Lim CM
Viruses; 2021 Feb; 13(2):. PubMed ID: 33671917
[TBL] [Abstract][Full Text] [Related]
36. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
37. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
38. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma.
Jiang W; Lv JW; Tang LL; Sun Y; Chen YP; Ma J
Cell Rep Med; 2024 Jun; 5(6):101594. PubMed ID: 38843843
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]